08:00 , Dec 15, 2014 |  BioCentury  |  Finance

Avanir Chronicles

Avanir Chronicles Avanir chroniclesThe $17 takeout price Otsuka Pharmaceutical Co. Ltd. will pay for Avanir Pharmaceuticals Inc. (NASDAQ:AVNR) is only a 13% premium to the neurology play's close the day before the $3.5 billion deal...
07:00 , Mar 24, 2014 |  BC Week In Review  |  Company News

Meda, Mission Pharmacal sales and marketing update

Mission Pharmacal received rights to promote Meda's Elestrin estradiol gel in the U.S. The bioidentical estradiol transdermal gel is approved in the U.S. to treat moderate to severe hot flashes and night sweats associated with...
07:00 , May 27, 2013 |  BioCentury  |  Finance

Value reality check

Europe's economic crisis has created a new reality. Austerity measures at the national level have placed an even higher premium than in the past on controlling healthcare costs, resulting in an increasingly tough reimbursement environment...
08:00 , Mar 4, 2013 |  BioCentury  |  Finance

Amgen's Omontys bounce

Amgen Inc. (NASDAQ:AMGN) added $2 billion in market cap last Monday, which was nearly four times the value shaved off competitor Affymax Inc. (NASDAQ:AFFY) when the latter recalled its once-monthly anemia drug Omontys peginesatide. Amgen...
07:00 , May 14, 2012 |  BioCentury  |  Finance

Vertex the odds-on favorite

Investors think there's still room to run for Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), which saw its valuation more than double last week on positive Phase II data for a drug combination that could treat nearly half...
07:00 , May 7, 2012 |  BioCentury  |  Strategy

Jazz's big band sound

A 2008 decision to concentrate on its commercial business has paid off for Jazz Pharmaceuticals Inc. The company has quadrupled its revenues, reduced its debt and increased its number of marketed drugs tenfold with two...
08:00 , Mar 5, 2012 |  BioCentury  |  Finance

Rothschild's bigger war chest

Edmond de Rothschild Investment Partners has determined that bigger is better and thus is out raising a €200 million ($268.5 million) fourth life sciences venture fund that will be larger than its €156 million ($242.9...
08:00 , Jan 30, 2012 |  BC Week In Review  |  Company News

Jazz Pharmaceuticals management update

Jazz Pharmaceuticals plc (NASDAQ:JAZZ), Dublin, Ireland   Business: Neurology, Endocrine/Metabolic   Hired: Fintan Keegan as SVP of technical operations, formerly SVP and chief technical officer of Azur Pharma Ltd. , which Jazz acquired; and Eunan...
08:00 , Jan 23, 2012 |  BC Week In Review  |  Company News

Azur Pharma, Jazz deal

Neurology company Jazz completed its acquisition of CNS and women's health company Azur in a stock deal. Jazz shareholders own 78% of the combined company. The combined company has 56.2 million shares outstanding, which translates...
07:00 , Oct 3, 2011 |  BioCentury  |  Finance

Cost averaging down

Even the best fundamentals may not be able to overcome the negative effects of the broader economy on the stock market this quarter. As a result, specialists have little hope of major gains and instead...